Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03797-0 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Dingyi Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71, He Di Road, Nanning, 530021, Guangxi, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Lung Neoplasms, Angiogenesis Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation Project, Chongqing Science and Health Joint Medical Research Project, Chongqing Talent Plan.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71, He Di Road, Nanning, 530021, Guangxi, China.
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China.
- School of Medicine, Chongqing University, Chongqing, China.
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China. zhouwei998@cqu.edu.cn.
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China. cqmdwyz@163.com.
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71, He Di Road, Nanning, 530021, Guangxi, China. zhuxdonggxmu@126.com.
Förderung
- National Natural Science Foundation Project
- Chongqing Science and Health Joint Medical Research Project
- Chongqing Talent Plan
- Key Research and Development Program Project of Guangxi Zhuang Autonomous Region
- Independent Project of Key Laboratory of Early Prevention & Treatment for Regional HighIncidence Tumor
Zitieren
APA
Yang, D., Munai, E., Zeng, S., Tao, D., Yuan, Z., Du, L., Zhou, W., Wu, Y., & Zhu, X. D. (2024). Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03797-0
Vancouver
Yang D, Munai E, Zeng S, Tao D, Yuan Z, Du L, et al. Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03797-0
BibTeX
@article{Yang2024,
author = {Yang, Dingyi and Munai, Erha and Zeng, Siwei and Tao, Dan and Yuan, Ze and Du, Liang and Zhou, Wei and Wu, Yongzhong and Zhu, Xiao-Dong},
title = {Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03797-0}
}
EUVIMED